We are a clinical late-stage pharmaceutical company focused on the development and commercialization of first-in-class pharmaceutical therapies for the treatment of ocular blinding diseases. Our product candidates are based on TRS, a New Chemical Entity, which is a potent local immunomodulatory agent. TRS is being developed as an eye drop formulation, TRS01, to treat the signs and symptoms of active uveitis in patients with uveitic glaucoma. TRS01 is currently being investigated in a phase-3 trial. The company is also developing TRS02, a slow-release formulation of the same compound, to be administered as intravitreal injections for the treatment of various back-of-the-eye inflammatory indications.